In:
Nanofabrication, Eurasia Academic Publishing Group, Vol. 7 ( 2022-06-09)
Abstract:
With the exponential rise in infections by CoV-2 and the scarcity of antiviral therapeutics, the development of an effective vaccine for the SARS CoV-2 is critical. The emerging pandemic has prompted the international science community to seek answers in therapeutic agents, including vaccines, to battle the SARS CoV-2. The various scientific literature on SARS CoV, to a lesser degree, MERS (Middle East Respiratory Syndrome), has mentored vaccine techniques for the unique Coronavirus. This disease, COVID-19, is triggered by SARS-CoV-2 virus that causes COVID-19 that needs vaccine protection. Vaccines producing significant amounts of virus-neutralizing antibodies with high affinity may be the only way to combat infection while avoiding negative consequences. There is a summary of numerous vaccine contenders in the review, including nucleotide, vector-based vaccines, & subunit, and attenuated & killed types. That has previously shown preventive effects against the MERS-CoV & SARS-CoV, while suggesting that these candidates may yield a safe and efficient vaccine for SARS-CoV-2. Vector-based vaccines, monoclonal antibodies, genetic vaccines, and protein subunit types for passive immunization are among the vaccination platforms currently being evaluated for the CoV-2 virus; each has its own set of benefits and drawbacks. The clinical safety and effectiveness evidence is the main challenging research task for this possible vaccine developed in the lab. The most challenging aspect of production is constructing and validating distribution platforms worthy of mass-producing the vaccine on a larger scale. Since target vaccine groups include high-risk people above the age of 60, including severe co-morbid diseases, the healthcare staff, and those engaged in vital industries, an effective COVID-19 vaccine would need a careful confirmation of effectiveness and detrimental reactivity. The study summarises efforts devoted to developing an efficient vaccine for the new Coronavirus that devastated the global economy, people's health, and even their lives.
Type of Medium:
Online Resource
ISSN:
2299-680X
DOI:
10.37819/nanofab.007.193
Language:
Unknown
Publisher:
Eurasia Academic Publishing Group
Publication Date:
2022
detail.hit.zdb_id:
2846487-4
